Magnetic resonance imaging in cervical cancer interventional radiotherapy (brachytherapy): a pictorial essay focused on radiologist management

Luca Russo, MD, Valentina Lancellotta, MD, Maura Miccò, MD, Bruno Fionda, MD, Giacomo Avesani, MD, Angeles Roixrosa, MD, PhD, Piotr Wojcieszek, MD, PhD, Prof. Giovanni Scambia, MD, Prof. Riccardo Manfredi, MD, Luca Tagliaferri, MD, PhD*, Benedetta Gui, MD*

*Equal contribution in this study.

1 Area Diagnostica per Immagini, Dipartimento Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Polidomico Universitario A. Gemelli IRCCS, Rome, Italy, 2 Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Polidomico Universitario A. Gemelli IRCCS, Rome, Italy, 3 Fonaments Clinics Department, Faculty of Medicine, University of Barcelona, Barcelona, Spain, 4 Department of Radiation Oncology, Hospital Clinic i Universitari, Barcelona, Spain, 5 Brachytherapy Department, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch, Gliwice, Poland, 6 UOC Ginecologia Oncologica, Dipartimento per la Salute della Donna e del Bambino e della Salute Pubblica, Fondazione Polidomico Universitario A. Gemelli IRCCS, Rome, Italy, 7 Istituto di Ginecologia e Ostetricia, Università Cattolica del Sacro Cuore, Rome, Italy, 8 Dipartimento Universitario di Scienze Radiologiche ed Ematologiche, Università Cattolica del Sacro Cuore, Rome, Italy

Abstract

The standard treatment for locally advanced cervical cancer (LACC) is platinum-based chemotherapy in association with external beam radiotherapy (EBRT) and brachytherapy (BT), often also called ‘interventional radiotherapy’ (IRT). Magnetic resonance imaging (MRI) is the most accurate imaging modality for both staging and response evaluation; therefore MRI-guided IRT has become the method of choice for planning a radiation boost after EBRT.

The aim of this paper was to describe the MRI radiological workflow currently ongoing at our Institution. In addition, we provided a detailed pictorial essay of our experience, especially for radiologists, to implement MRI-based IRT spread in clinical practice.

J Contemp Brachytherapy 2022; 14, 3: 287–298
DOI: https://doi.org/10.5114/jcb.2022.117727

Key words: brachytherapy, magnetic resonance imaging, cervical cancer.

Purpose

Cervical cancer accounted for approximately 570,000 in 2018, becoming the fourth most frequent cancer in women [1]. Treatment depends on FIGO stage at diagnosis [2], performance status, and patients’ compliance.

Locally advanced cervical cancer (LACC), including stage IB3-IVA, is usually treated with platinum-based chemotherapy in association with external beam radiotherapy (EBRT), followed by brachytherapy (BT), often also called ‘interventional radiotherapy’ (IRT) [3, 4]. Magnetic resonance imaging (MRI) is the most accurate imaging modality for both staging and response evaluation after concurrent chemoradiation therapy (CCRT) [2, 5].

Interventional radiotherapy in cervical cancer had advanced in the last ten years, using three-dimensional (3D) imaging and technological innovations [6-8]. Among imaging modalities, MRI is considered the most accurate imaging modality, compared with pathologic specimen, in the evaluation of the cervix tumor volume [9-12]. Several studies have proven that patient outcome improves using MRI in cervical cancer treatment [13-20]. MRI-guided IRT has been first proposed in 1992 [21], and since then has become the method of choice for planning IRT [22].

Image-guided IRT (IG-IRT) utilization is recently increasing; most of the centers use MRI-based planning at the first fraction, while few centers utilize MRI-based planning for each fraction [23]. It is due to the number of MRI scanner, increased effort demands, and a longer scan time.

The aim of this paper was to describe the MRI radiological workflow currently ongoing at our Institution.
Furthermore, we provided a detailed MRI and IRT workflow, and a step-by-step approach in order to help, especially radiologists, in implementation of effective MRI-based IRT into general clinical practice.

**Material and methods**

**Treatment procedure**

Between July 2020 and April 2021, 65 consecutive patients with LACC underwent MRI-based IRT, following Gynecological Groupe Européen de Curietherapie-European Society for Radiotherapy and Oncology working group contouring and planning guidelines (Recommendations I and II by working group) [9, 24]. MR-safe applicators were used for all patients. Oncentra (Oncentra® Brachy treatment planning; Elekta, Sweden) system was applied to plan all treatments. Treatment was delivered using Elekta Flexitron afterloading machines with iridium-192 ($^{192}$Ir) source.

Based on our protocol, interventional radiotherapy boost to high-risk clinical target volume (HR-CTV) and intermediate-risk CTV (IR-CTV) is performed after 45 Gy delivered with EBRT to low-risk CTV, IR-CTV, and HR-CTV, following GEC-ESTRO guidelines. The total IRT dose is 28 Gy to achieve a dose between 85 Gy to 95 Gy EQD$_2$ ($\alpha/\beta = 10$Gy) to D$_{90}$ HR-CTV, and 14 Gy to IR-CTV in four high-dose-rate (HDR) fractions in order to achieve a D$_{90} > 60$ Gy EQD$_2$ ($\alpha/\beta = 10$Gy) [9].

The treatment was arranged following an internal protocol: 1) baseline MRI (staging MRI), 2) EBRT, 3) post-EBRT pelvic MRI (post-EBRT MRI: day 1), 4) first applicator insertion (day 1), 5) pelvic MRI with applicators (post-applicator insertion MRI: day 1), 6) first and second fractions treatment planning, delivery, and applicator removal (day 1 and day 2), 7) second applicator insertion, third and fourth fractions treatment planning, delivery and applicator removal (day 10 and day 11). Time associated with delivery of first fraction was recorded. Details regarding the first insertion are presented in Figure 1. Computed tomography (CT) was performed for every IRT fraction to elaborate treatment planning for each treatment (1st, 2nd, 3rd, and 4th fractions). Planning CT images were acquired with 0.625 mm slice thickness and transmitted to treatment planning system (Oncentra).

**Workflow planning**

Our Institution’s MRI room is located close to the interventional oncology center (operative room and HDR-IRT bunker), taking 3-5 minutes to transfer patients between the two areas.

**MRI protocol (for staging and evaluation post-EBRT, before and after applicator positioning)**

Staging MRI and post-EBRT MRI were performed for all patients with a 1.5 T MR scanner (Echospeed Horizon and Infinity, General Electric Healthcare, GE), using a standard 8-channel phased-array body coil. MRI sequences included conventional MRI and diffusion-weighted imaging (DWI) sequences. Intra-muscu-

---

**On the same day**

| Baseline MRI | Post-EBRT MRI (27 minutes) | Applicator insertion (30-45 minutes) | MRI with appl. (8 minutes) | Treatment delivery (45-60 minutes) |
|--------------|-----------------------------|--------------------------------------|-----------------------------|-----------------------------------|
| • Staging    | • No applicator             | • General anesthesia                 | • Organ at risk and         |                                   |
| • I.m. butylscopolamine | • I.m. butylscopolamine| • Placement of a Foley catheter      | target volume               |                                   |
|              | • Treatment response        | • Intreutereal applicator insertion  | delineation                 |                                   |
|              | evaluation after EBRT      | • Insertion rectal probe             | • Treatment planning        |                                   |
|              |                             |                                      | • Treatment delivery        |                                   |

**Fig. 1. Workflow currently in use at our Institution**
lar butylscopolamine (1 mg of buscopan, Schering) was administered to reduce bowel peristalsis. Conventional sequences included axial T2- and T1-weighted fast spin echo (FSE) sequence, high resolution FSE T2-weighted images in different imaging planes (sagittal/oblique axial and oblique coronal, respectively, perpendicular and parallel to the long axis of cervix). DWI sequence was performed on the same orientation of axial oblique FSE.

### Table 1. Magnetic resonance imaging protocol for evaluation of patients with cervical carcinoma after external beam radiotherapy (EBRT)

| Parameter | Axial upper and lower abdomen T2-W | Sagittal T2-W | Axial T1-W | Coronal oblique T2-W | Axial oblique T2-W | Axial oblique DW | Axial upper and lower abdomen DW |
|-----------|-----------------------------------|--------------|------------|----------------------|-------------------|----------------|---------------------------------|
| Sequence  | FSE propeller                     | FSE propeller| FSE        | FSE                  | FSE propeller     | EPI            | EPI                             |

| Imaging time | | | | | | | |
|---------------|----------------|--------------|------------|----------------------|-------------------|----------------|---------------------------------|
| Echo time (msec) | 74 | 113.8 | Minimum full | 98 | 125.4 | Minimum full | Minimum full |
| No. of signals acquired | 2 | 1.5 | 1 | 4 | 3 | 6-16 | 6-14 |
| Repetition time (msec) | 6,000-7,000 | 7,150 | 500-700 | 4,500 | 4,000-5,000 | > 6,000 | 8,000 |
| No. of sections | 80 | 29 | 38 | 22 | 18 | 40 | 43 + 43 |
| Receiver bandwidth (kHz) | 50 | 41.67 | 27.78 | 35.71 | 35.71 | – | 250 |
| Echo train length | 23 | 32 | 3 | 23 | 36 | – | – |

### Table 2. Magnetic resonance imaging protocol for evaluation of patients with cervical carcinoma after EBRT

| Parameter | Sagittal T2-W | Axial T2-W | Coronal T2-W |
|-----------|---------------|------------|--------------|
| Sequence  | FRFSE propeller | FRFSE | FRFSE |

| Imaging time | | | |
|---------------|----------------|--------------|------------|
| Echo time (msec) | 114 | 85 | 85 |
| No. of signals acquired | 1.5 | 2 | 2 |
| Repetition time (msec) | 5,000-7,000 | 4,000-5,000 | 3,282 |
| No. of sections | 23 | 26 | 16 |
| Receiver bandwidth (kHz) | 41.67 | 41.67 | 41.67 |
| Echo train length | 32 | 19 | 23 |

| Imaging range | | | |
|---------------|----------------|--------------|------------|
| Field of view (mm) | 260 | 260 | 260 |
| Section thickness (mm) | 4 | 3 | 3 |
| Section spacing (mm) | 0.4 | 0.3 | 0.3 |
| Matrix size | 320 × 320 | 320 × 320 | 288 × 256 |
| Phase direction | Posterior-anterior | Inferior-superior | Inferior-superior |
| Imaging options | NPW | NPW | NPW |
| Acquisition time (min:sec) | 06:12 | 3:42 | 1:49 |

DWI – diffusion weighted, EPI – echo-planar imaging, FSE – fast spin-echo, GRE – gradient-recalled echo; NPW – no phase wrap, SSFSE – single-shot FSE.
T2-WI, using single-shot diffusion-weighted echo-planar sequence, including two b-values (degree of diffusion weighting applied: 0 and 1,000 s/mm²). Axial T2-WI single-shot fast spin echo (SSFSE) and balanced steady-state gradient echo sequence (FIESTA, GE brand) were acquired up to the renal hila, to assess eventual lumbo-aortic lymphadenopathy and/or hydronephrosis. Detailed acquisition protocol is reported in Table 1.

After applicator insertion, patients were re-scanned with 1.5 T MRI. Post-applicator positioning MRI was performed with fast imaging protocol, including only high resolution FSE T2-WI in three planes (axial, sagittal, and coronal) according to tandem applicator axis (Table 2). The aim of this scan was to assess correct positioning of the tandem and its’ position relatively to the cervix and/or the residual tumor, to accurately plan IRT treatment.

**Applicator insertion**

The positioning of the applicator was performed under general anesthesia. A Foley catheter was positioned into the bladder. After dilatation of the cervical canal, the applicator was placed using a transrectal US-guided procedure to ensure the correct position and reduce the risk of uterus perforation. The IRT applicator would serve as a canal for transportation of radioactive source.

The applicator must be MR-safe. Different applicator models are commercially available. It can be made of stainless steel, titanium, or plastic, and is composed of two main parts, including central tandem with ovoids or central tandem with ring. The central tandem is located inside the uterus canal, functioning as a stabilizer and means of passage of the radioactive source to the cervix and the uterus. The ovoids or ring are attached to the lower part of the tandem, and are usually allocated in the vaginal fornices leaning on the cervix. In case of parametrial involvement, interstitial IRT is recommended.

Then, rectal probe is placed in the rectum to confirm the correct positioning of the implant.

**Treatment planning**

Organs at risk (OARs), IR-CTV, and HR-CTV were delineated as follows:

Organs at risk: Delineation of the rectum, bladder, sigmoid, and small bowel following their other contour.

Target volume delineation: IR-CTV carrying a significant microscopic tumor load, encompassed HR-CTV with a safety margin of 5-15 mm (with the exclusion of OARs). Amount of safety margin was chosen according to the tumor size and location, potential tumor spread, tumor regression, and treatment strategy.

HR-CTV included cervix + visible/palpable disease and gross tumor volume (GTV) – T2 bright areas [9]. Dose reporting was based on the total (EBRT + IRT) biologically equivalent dose in 2 Gy fractions (EQD2). Planning purposes were to deliver a minimum of 60 Gy to 90% isodose volume (D90), including IR-CTV, at least 85 Gy to D90 of HR-CTV, and more than 90 Gy to D80 of GTV preserving the established D2cc (the minimum doses calculated at the most irradiated 2cc volume) at OARs.

**Focus on MRI role**

**Staging MRI and post-EBRT MRI: Staging and treatment response evaluation**

MRI has shown high accuracy in cervical cancer evaluation, mainly for tumor size, assessment of deep stromal invasion, and parametrial invasion (specificity 97%, negative predictive value [NPV] 100%) [25, 26]. In addition, internal os involvement can be assessed on MRI with high sensitivity (90%) and specificity (98%).

At our Institution, response evaluation criteria in solid tumors (RECIST) version 1.1 are used to evaluate re-

---

### Baseline and post-CRT MRI

**Uterus**
- Size: length, antero-posterior and transverse diameter
- Aspect

**Cervix:**
- lesion yes/no
- If lesion:
  - Signal intensity on T2-WI and DWI
  - Location: cervical canal/exo-cervix

**Invasion of:**
- Stromal ring
  - Side: right/left/circumferential
  - Full thickness: yes/no
- Parametria
  - Side: right/left/bilateral
  - Degree: proximal/intermediate/lateral
  - Vagina
  - Upper third (vaginal fornices)/middle third/lower third

**Fig. 2.** Baseline and post-external beam radiotherapy (EBRT) template report
Fig. 3. Post-external beam radiotherapy (EBRT) recto-vaginal fistula. Baseline and post-EBRT MRI in 72-year-old woman with squamous cervical carcinoma. At baseline MRI (A, C), T2-w sequences show the hyperintense cervical mass, extending to the upper third of the vagina, with maximum diameter of 50 mm (any plane). After concurrent EBRT (B, D), T2-w sequences show the presence of an hyperintense area in the posterior wall of the cervix and posterior vaginal fornix. Post-EBRT MRI presents a rectovaginal fistula (arrow).

Response to CCRT [27]. In case of complete response (CR) or partial response (PR)/stable disease (SD), patients are suitable for IRT. The standard method to assess the response to EBRT is to evaluate tumor size modification on post-EBRT MRI. Tumor size reduction is indicative of a good prognosis in LACC [28]. Full-thickness T2-WI low signal intensity is an indicator of reconstitution of cervical stroma integrity, configuring complete response to EBRT (NPV = 97%) [29]. However, hyperintense signal can be still visible on T2-WI, representing EBRT-induced inflammation, oedema, and necrosis [30].

DWI can improve detection of residual tumor, presenting as a focal hyperintense area on T2-WI and DWI, with corresponding hypointensity on the apparent diffusion coefficient (ADC) map [31, 32]. MRI evaluation of tumor response after therapy requires a comparative evaluation with staging MRI, in order to better interpret the imaging findings.

ADC can be helpful in differentiating residual tumor from post-radiotherapy fibrosis. Modifications of ADC value during and after EBRT have been associated with response to treatment and survival [33]. However, ADC
value use is limited because of variable cut-offs reported in literature [34].

Concerning dynamic contrast enhancement (DCE) MRI, there is no consensus regarding its role for tumor response evaluation after EBRT treatment [34]. Some studies found that time-signal intensity evaluations are associated with treatment response [35, 36]. In our department, gadolinium-based contrast agent is not administered neither at staging MRI nor at post-EBRT MRI.

At our Institution, a standardized pro-forma reporting is used (Figure 2) for both staging MRI and post-EBRT MRI for correct staging of the tumor and evaluation of the response after EBRT, according to RECIST version 1.1. Moreover, every parameter and important sites of tumor extension are reported and compared between staging MRI and post-EBRT MRI.

Mandatory findings include tumor diameter, cervical stroma invasion, parametrial invasion, vaginal invasion, uterus corpus/fundus invasion, hydronephrosis, relationship with adjacent organs (bladder/rectum), and lymph nodes.

The type of applicator is evaluated on case-by-case basis, and if post-EBRT MRI shows evidence of progressive disease or vesicouterine or rectouterine/rectovaginal fistula, a deep discussion is done in order to define the best personalized approach (Figure 3). On T2-WI, fistulas are seen as high signal intensity breach of the wall between cervix/vagina and the rectum or bladder. Sagittal plane is the most appropriate one for the detection of fistulas. These findings must be promptly reported and considered for next treatments planning.

CCRT can be a cause of ancillary findings, especially inflammatory ones regarding the rectum, sigmoid, and bladder. Radiologists must be aware of these because patients are often asymptomatic. Free fluid in the pouch of Douglas

Fig. 4. Cervical cancer in a 55-year-old woman who underwent MR imaging with applicator. Sagittal (A), axial (B), and coronal (C) images, respectively, perpendicular and parallel to the plane of the applicator show tandem (arrow) in place. On axial plane (B), tumor (T) is located around the tandem from 7 to 1 o’clock (dotted line)
MRI with applicator
Intrauterine applicator in place/not in place
- Ovoids/ring (vaginal fornices)
- Tandem (endometrial cavity)
Cervix residual tumor: yes/no
If residual tumor:
- Location
- Size: length, antero-posterior, and transverse diameter
- Tumor-tandem relationship
  Circumferential/clockwise (ex. from 1 to 6)
  Maximum tumor thickness (on axial plane: from tandem towards stromal ring/parametrium)
- Parametrial invasion: yes/no
  Side
  Tumor-to-applicator thickness

Fig. 5. MRI with applicator template report

MRI with applicator
- Vaginal invasion: yes/no
  Upper third (vaginal fornices)/middle third/lower third
  Tumor-to-applicator length
Additional findings: (in case incorrect positioning of the applicator)
- Free fluid, air, others

Fig. 6. 31-year-old woman with squamous cervical carcinoma treated with EBRT. Post-external beam radiotherapy (EBRT) images (A, B) show reconstitution of low signal intensity of cervical stroma (arrows in B). C, D) Post-applicator MRI. Images show correct positioning of applicator within endometrial cavity (arrowhead) and ring in vaginal fornices (asterisk)
Fig. 7. 59-year-old woman with squamous cervical carcinoma treated with external beam radiotherapy (EBRT). Post-EBRT images (A, B) show reconstitution of low signal intensity of cervical stroma (arrows in B). C, D) Post-applicator MRI. Images show correct positioning of applicator within the endometrial cavity (arrowhead) and ovoids in vaginal fornices (asterisk).

Evaluation after applicator positioning

Post-applicator MRI serves to evaluate applicator positioning and provide support to IRT planning, in terms of tumor position and extension related to the applicator (Figure 4). Radiologists dealing with MRI-guided IRT are required to know specific parts of the applicator (ring, ovoids, tandem, etc.) and how to use the device. Surgical packing can be detected in vaginal cavity around the applicator, as low-signal intensity material, and should not be mistaken as hemorrhage or residual tumor. At our Institution, it is possible to perform endocavitary and interstitial IRT procedure. If residual tumor is detected, its’ relationship with the tandem/any vaginal applicator should be described.

A structured report is currently in use at our Institution for post-applicator positioning MRI (Figure 5). This report includes useful findings for interventional radiation oncologists during IRT treatment planning. Firstly, type and position of the applicator considering location of tandem and ovoids or ring are described (Figures 6, 7). Secondly, relationships between the tandem and eventual residual tumor are defined (Figures 8, 9). In details, cranio-caudal extension of residual tumor and its’ location and maximum thickness are reported using a clockwise system (Figures 10, 11).

After EBRT, cervical and uterine tissues change after radiation, and for this reason, a uterine perforation can occur. US-guided insertion and post-applicator MRI enable accurate detection of this complication [37, 38].

On MRI images, the adjacent OARs are identified [9, 10]. At our Institution, GTV, HR-CTV, IR-CTV, and OARs are segmented by radiation oncologist, who, whenever
Fig. 8. Tumor maximum thickness: axial oblique T2-weighted FSE image perpendicular to the plane of the applicator (A) shows tumor extension within cervical stroma (arrow with maximum tumor extension (dotted line) from the tandem (arrowhead) within the cervical stroma at 9 o’clock) (B). Schematic illustration of the tumor maximum thickness (C)

Fig. 9. Maximum tumor length: coronal oblique T2-weighted FSE image in the plane with the applicator (A) shows maximum tumor length (dotted line) from the ring (*), along with the tandem (arrow) (B). Schematic illustration of the tumor maximum thickness (C)
necessary, reviews images with the radiologist [9, 10]. After plan optimization approving, procedures are applied: • radiation oncologist approval, • calculation check by physicist, • review by therapists.

Then, the treatment is delivered.

**Conclusions**

The workflow currently ongoing at our Institution was presented. 1.5 T MRI is performed before and after cervix applicator insertion, with unquestionable advantages. First, MRI is the imaging modality of choice for staging and treatment response assessment due to high accuracy in cervical cancer evaluation (tumor size, assessment of deep stromal invasion, and parametrial invasion).

After concurrent EBRT, MRI with DWI provides accurate evaluation of treatment response. Furthermore, MRI scan after applicator insertion is essential for the evaluation of correct cervix applicator insertion, and provides accurate assistance for IRT treatment planning in order to achieve personalized approach.

**Disclosure**

The authors report no conflict of interest.
MRI-guided brachytherapy for radiologists

Fig. 11. 55-year-old woman with squamous cell cervical carcinoma. Post-external beam radiotherapy (EBRT) coronal and axial oblique FSE T2-weighted images (A, B) show high signal-intensity residual tumor (T) in the right stromal portion and in the right vaginal fornix. Post-applicator coronal T2-weighted image (C) presents the relationship between the applicator and the residual tumor (arrow)

References

1. Bray F, Ferlay J, Soerjomataram I et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68: 394-424.
2. Bhatla N, Aoki D, Sharma DN et al. Cancer of the cervix uteri. Int J Gynaecol Obstet 2018; 143 Suppl 2: 22-36.
3. Koh WJ, Abu-Rustum NR, Bean S et al. Cervical cancer, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2019; 17: 64-84.
4. Campitelli M, Lazzari R, Piccolo F et al. Brachytherapy or external beam radiotherapy as a boost in locally advanced cervical cancer: a Gynaecology Study Group in the Italian Association of Radiation and Clinical Oncology (AIRO) review. Int J Gynecol Cancer 2021; 31: 1278-1286.
5. Fournier LS, Bats AS, Durdux C. Diffusion MRI: Technical principles and application to uterine cervical cancer. Cancer Radiother 2020; 24: 368-373.
6. Kim H, Beriwal S, Houser C et al. Dosimetric analysis of 3D image-guided HDR brachytherapy planning for the treatment of cervical cancer: is point A-based dose prescription still valid in image-guided brachytherapy? Med Dosim 2011; 36: 166-170.
7. Mayadev J, Viswanathan A, Liu Y et al. American Brachytherapy Task Group Report: a pooled analysis of clinical outcomes for high-dose-rate brachytherapy for cervical cancer. Brachytherapy 2017; 16: 22-43.
8. Soror T, Siebert FA, Lancellotta V et al. Quality assurance in modern gynecological HDR-brachytherapy (Interventional Radiotherapy): clinical considerations and comments. Cancers (Basel) 2021; 13: 912.
9. Haie-Meder C, Potter R, Van Limbergen E et al. Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group (I): concepts and terms in 3D image based 3D treatment planning in cervix cancer brachytherapy with emphasis on MRI assessment of GTV and CTV. Radiother Oncol 2005; 74: 235-245.
10. Harkenrider MM, Alite F, Silva SR et al. Image-based brachytherapy for the treatment of cervical cancer. Int J Radiat Oncol Biol Phys 2015; 92: 921-934.
11. Owranji AM, Prisciandaro JJ, Soliman A et al. Magnetic resonance imaging-guided brachytherapy for cervical cancer: initiating a program. J Contemp Brachytherapy 2015; 7: 417-422.
12. Tanderup K, Viswanathan AN, Kirisits C et al. Magnetic resonance image guided brachytherapy. Semin Radiat Oncol 2014; 24: 181-191.
13. Chargari C, Magne N, Dumas I et al. Physics contributions and clinical outcome with 3D-MRI-based pulsed-dose-rate intracavitary brachytherapy in cervical cancer patients. *Int J Radiat Oncol Biol Phys* 2009; 74: 133-139.

14. Dimopoulos JC, Potter R, Lang S et al. Dose-effect relationship for local control of cervical cancer by magnetic resonance image-guided brachytherapy. *Radiother Oncol* 2009; 93: 311-315.

15. Gill BS, Kim H, Houser CJ et al. MRI-guided high-dose-rate intracavitary brachytherapy for treatment of cervical cancer: the University of Pittsburgh experience. *Int J Radiat Oncol Biol Phys* 2015; 91: 540-547.

16. Mahantheshetty U, Swamidas J, Khanna N et al. Reporting and validation of gynaecological Groupe Europeen de Curietherapie European Society for Therapeutic Radiology and Oncology (ESTRO) brachytherapy recommendations for MR image-based dose volume parameters and clinical outcome with high dose-rate brachytherapy in cervical cancers: a single-institution initial experience. *Int J Gynecol Cancer* 2011; 21: 1110-1116.

17. Nomden CN, de Leeuw AA, Roesink JM et al. Clinical outcome and dosimetric parameters of chemo-radiation including MRI guided adaptive brachytherapy with tandem-ovoid applicators for cervical cancer patients: a single institution experience. *Radiother Oncol* 2013; 107: 69-74.

18. Potter R, Dimopoulos J, Georg P et al. Clinical impact of MRI assisted dose volume adaptation and dose escalation in brachytherapy of locally advanced cervix cancer. *Radiother Oncol* 2007; 83: 148-155.

19. Potter R, Georg P, Dimopoulos JC et al. Clinical outcome of protocol based image (MRI) guided adaptive brachytherapy combined with 3D conformal radiotherapy with or without chemotherapy in patients with locally advanced cervical cancer. *Radiother Oncol* 2011; 100: 116-123.

20. Sturzdza A, Potter R, Fokdal LU et al. Image guided brachytherapy in locally advanced cervical cancer: Improved pelvic control and survival in RetroEMBRACE, a multicenter cohort study. *Radiother Oncol* 2016; 120: 428-433.

21. Schoeppe SL, Ellis JH, LaVigne ML et al. Magnetic resonance imaging during intracavitary gynecologic brachytherapy. *Int J Radiat Oncol Biol Phys* 1992; 23: 169-174.

22. Beddy P, Rangarajan RD, Sala E. Role of MRI in intracavitary brachytherapy for cervical cancer: what the radiologist needs to know. *AJR Am J Roentgenol* 2011; 196: W341-347.

23. Grover S, Harkenrider MM, Cho LP et al. Image guided cervix brachytherapy: 2014 Survey of the American Brachytherapy Society. *Int J Radiat Oncol Biol Phys* 2016; 94: 598-604.

24. Potter R, Haie-Meder C, Van Limbergen E et al. Recommendations from gynaecological (GYN) GEC ESTRO working group (II): concepts and terms in 3D image-based treatment planning in cervix cancer brachytherapy-3D dose volume parameters and aspects of 3D image-based anatomy, radiation physics, radiobiology. *Radiother Oncol* 2006; 78: 67-77.

25. Sahdev A, Sohaib SA, Wenaden AF et al. The performance of magnetic resonance imaging in early cervical carcinoma: a long-term experience. *Int J Gynecol Cancer* 2007; 17: 629-636.

26. Epstein E, Testa A, Gaurilcikas A et al. Early-stage cervical cancer: tumor delineation by magnetic resonance imaging and ultrasound – a European multicenter trial. *Gynecol Oncol* 2013; 128: 449-453.

27. Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). *Eur J Cancer* 2009; 45: 228-247.

28. Angeles MA, Baissas P, Leblanc E et al. Magnetic resonance imaging after external beam radiotherapy and concurrent chemotherapy for locally advanced cervical cancer helps to identify patients at risk of recurrence. *Int J Gynecol Cancer* 2019; 29: 480-486.

29. Sala E, Rockall AG, Freeman SJ et al. The added role of MR imaging in treatment stratification of patients with gynecologic malignancies: what the radiologist needs to know. *Radiology* 2013; 266: 717-740.

30. Vincens E, Balleyguier C, Rey A et al. Accuracy of magnetic resonance imaging in predicting residual disease in patients treated for stage IB2/II cervical carcinoma with chemoradiation therapy: correlation of radiologic findings with surgical-pathologic results. *Cancer* 2008; 113: 2158-2165.

31. Gui B, Micco M, Valentini AL et al. Prospective multimodal imaging assessment of locally advanced cervical cancer patients administered by chemoradiation followed by radical surgery – the “PRICE” study 2: role of conventional and DW-MRI. *Eur Radiol* 2019; 29: 309-318.

32. Thomeer MG, Vandeaveeye V, Braun L et al. Evaluation of T2-W MR imaging and diffusion-weighted imaging for the early post-treatment local response assessment of patients treated conservatively for cervical cancer: a multicentre study. *Eur Radiol* 2019; 29: 309-318.

33. Erbay G, Onal C, Karadeli E et al. Predicting tumor recurrence in patients with cervical cancer treated with definitive chemoradiotherapy: value of quantitative histogram analysis on diffusion-weighted MR images. *Acta Radiol* 2017; 58: 481-488.

34. Manganaro L, Lakhman Y, Bharwani N et al. Staging, recurrence and follow-up of uterine cervical cancer using MRI: Updated Guidelines of the European Society of Urogenital Radiology after revised FIGO staging 2018. *Eur Radiol* 2021; 31: 7802-7816.

35. Jalaguier-Coudray A, Villard-Mahjoub R, Delouche A et al. Value of dynamic contrast-enhanced and diffusion-weighted MR imaging in the detection of pathologic complete response in cervical cancer after neoadjuvant therapy: a retrospective observational study. *Radiology* 2017; 284: 432-442.

36. Mayr NA, Wang JZ, Zhang D et al. Longitudinal changes in tumor perfusion pattern during the radiation therapy course and its clinical impact in cervical cancer. *Int J Radiat Oncol Biol Phys* 2010; 77: 502-508.

37. Sullivan T, Yacoub JH, Harkenrider MM et al. Providing MR imaging for cervical cancer brachytherapy: lessons for radiologists. *Radiographics* 2018; 38: 932-944.

38. Viswanathan AN, Beriwal S, De Los Santos JF et al. American Brachytherapy Society consensus guidelines for locally advanced carcinoma of the cervix. Part II: high-dose-rate brachytherapy. *Brachytherapy* 2012; 11: 47-52.